insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

LIXT · Lixte Biotechnology Holdings, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · LIXT

1Y3YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$333.4K-$50.7K$60.6K$91.5K-$361.6K$210.7K$119.1K-
SG&A$1.65M-$1.75M$714.2K$615.5K-$283.1K$306.4K$317.7K-
Total Operating Expenses$1.99M-$1.80M$774.8K$706.9K-$983.3K$1.01M$966.9K-
D&A----------
Operating Income($1.99M)-($1.80M)($774.8K)($706.9K)-($983.3K)($1.01M)($966.9K)-
Interest Expense$3.1K-$457$1.8K$3.1K-$1.0K$4.2K$7.2K-
Income Tax----------
Net Income($1.94M)-($1.98M)($775.7K)($709.6K)-($986.0K)($1.01M)($971.3K)-
EPS - Basic($0.18)-($0.33)($0.29)($0.29)-($0.44)($0.45)($0.43)-
EPS - Diluted($0.18)-($0.33)($0.29)($0.29)-($0.44)($0.45)($0.43)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$3.25M$5.11M$2.89M$887.2K$1.38M$1.04M$1.64M$2.60M$3.41M$4.20M
Accounts Receivable----------
Inventory----------
Accounts Payable----------
Current Assets$3.41M$5.18M$5.43M$989.8K--$1.69M$2.67M$3.59M$4.31M
Total Assets$10.87M$12.73M$5.43M$1.19M$1.51M$1.15M$1.70M$2.67M$3.59M$4.31M
Current Liabilities$1.22M$1.33M$521.4K$537.1K$355.1K$318.3K$329.0K$421.5K$462.8K$313.9K
Long-term Debt----------
Total Liabilities$1.69M$1.77M---$318.3K----
Stockholders' Equity$7.95M$9.66M$4.91M$651.5K$1.16M$827.2K$1.37M$2.25M$3.13M$3.99M
Retained Earnings($60.00M)($58.08M)($55.53M)($53.55M)($52.78M)($52.07M)($51.45M)($50.46M)($49.45M)($48.48M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($1.83M)---($568.5K)---($789.2K)-
Investing Cash Flow($24.9K)---------
Financing Cash Flow----$914.2K-----
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-17.9%--36.4%-65.3%-46.9%--58.1%-37.9%-27.1%-
Return on equity-24.4%--40.3%-119.1%-61.2%--72.1%-45.0%-31.1%-
Return on invested capital----------
Liquidity
Current ratio2.783.8810.421.84--5.136.337.7513.73
Quick ratio2.783.8810.421.84--5.136.337.7513.73
Cash ratio2.653.835.541.653.903.264.986.167.3813.39
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage-641.9x--3941.7x-428.1x-225.5x--937.3x-242.9x-134.6x-
Equity multiplier1.371.321.111.821.311.381.241.191.151.08
Liabilities / Assets0.160.14---0.28----
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B4.2x-6.3x3.8x2.6x-3.1x2.4x2.4x-
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-181.1%--83.2%23.2%26.9%-4.0%39.6%29.4%-
Net income growth (YoY)-173.6%--100.8%23.3%26.9%-3.2%39.4%29.0%-
EPS growth (YoY)37.9%-25.0%35.6%32.6%-10.2%55.0%--
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)585.4%1068.3%259.4%-71.0%-62.9%-79.3%-72.2%-16.6%-23.4%-22.7%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing LIXTE BIOTECHNOLOGY HOLDINGS against the 5 most active filers in the same SIC group.